CD2H COVID-19

A Study of the GRIP Influenza and SARS-CoV-2 POC Assays

Purpose

The purpose of this research is to determine if the use of a new device can accurately detect a virus infection.

Conditions

COVID-19
Influenza

Eligibility

Eligible Ages: Over 18 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Patients being tested for COVID 19 or Influenza

Exclusion Criteria

Patients < 18 years of age

Study Design

Phase: N/A
Study Type: Interventional
Allocation: N/A
Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental Novel, graphene-based, point-of-care device	Subjects will receive one additional nasal swab at the same time as clinical collection.	Device: GRIP Electronic Diagnostic Chip Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab Diagnostic Test: Laboratory-based nucleic acid amplification tests (NAATs) Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab

Recruiting Locations

More Details

NCT ID: NCT05674370
Status: Completed
Sponsor: Mayo Clinic

Detailed Description

GRIP has developed a novel, graphene-based detection system for potential use in point-of-care settings. This study will compare the performance of the GRIP device to routine PCR testing for detection of COVID-19 and influenza viruses. When patients present for routine testing for COVID-19 and influenza, they will also have a separate nasal swab collected that will be tested by the GRIP point-of-care device.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.